A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA186498-01A1
Agency Tracking Number: R41CA186498
Amount: $160,996.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2015
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-03-01
Award End Date (Contract End Date): 2017-02-28
Small Business Information
2693 GLENROSE HILL, Atlanta, GA, 30341-5785
DUNS: 078866511
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DAQING WU
 (404) 778-4845
 dwu2@emory.edu
Business Contact
 DAQING WU
Phone: (404) 771-1300
Email: daqingwu@hotmail.com
Research Institution
 EMORY UNIVERSITY
 1599 CLIFTON ROAD, 4TH FLOOR
ATLANTA, GA, 30322-4250
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Castration Resistant Prostate Cancer Castration resistant prostate cancer CRPC directly contributes to patient mortality It is imperative to develop new and effective adjunct therapy to enhance the response of CRPC to hormonal therapy Recently we developed ProFineTM a proprietary formula consisting of bioactive flavonoids enriched in pomegranate fruit and demonstrated its potent anti cancer activity in CRPC cells In this Phase I STTR application we hypothesize that ProFineTM potently co targets AR and Akt signaling thereby activating apoptosis in CRPC cells and sensitizing them to androgen deprivation therapy ADT Two Aims are proposed Aim will determine the mechanism of action of ProFineTM in CRPC cells specifically how ProFineTM inhibits androgen receptor signaling Aim will evaluate the efficacy of ProFineTM in enhancing enzalutamide hormonal therapy in an orthotopic model of CRPC Accomplishment of the proposed studies will provide solid evidence for future patent application and a Phase II STTR application PUBLIC HEALTH RELEVANCE American Cancer Society estimated that new cases will be diagnosed with prostate cancer PCa in and patients will die mostly from castration resistant disease CRPC It is imperative to develop safe efficacious and cost effective adjunct therapy to enhance the response of CPRC to standard therapies In this Phase I STTR application we will develop ProFineTM a pomegranate derived flavonoid formula as an effective adjunct treatment to enzalutamide therapy in CRPC It is expected that as a dietary supplement ProFineTM can be rapidly commercialized and approved for clinical trials This proposal has profound impact due to its immediate potentia l in treating a lethal disease reducing cancer morbidity and improving healthcare in the United States and globally

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government